Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Bone Marrow Transplantation for Pediatric Patients

    ... with an overview of the transplant process, including HLA matching, protecting your child’s fertility and preparing your child ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  2. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    ... U. S. Department of Health and Human Services. HLA typing will be performed by high resolution molecular DNA typing for HLA Class I A, B, and C and HLA Class II DRB1 and DQB1 alleles. ...

    Clinical Trial last updated 06/13/2016 - 2:06pm.

  3. Clinical Trials Report for April 2016

    ... for patients with human leukocyte antigen ( HLA ) matched unrelated (MUD) and mismatched unrelated (MMUD) donors. ...

    Page last updated 08/10/2016 - 11:00am.

  4. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... there should be no readily available consenting HLA - matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB1. No availability of a readily available HLA-matched ...

    Clinical Trial last updated 06/06/2016 - 3:37pm.

  5. Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia

    ... to 80%. Patients must have a related, genotypically HLA identical donor, or they must have a unrelated donor who is 8/8 HLA match by high resolution typing. Patient or patient's legal ...

    Clinical Trial last updated 06/06/2016 - 11:07am.

  6. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... there should be no readily available consenting HLA - matched related donor who is either matched fully matched or mismatched at only one locus of HLA-A, -B, and DRB1. No availability of a readily available HLA-matched ...

    Clinical Trial last updated 06/03/2016 - 2:54pm.

  7. Adoptive Transfer of Haplo-identical DLI for AML and MDS

    ... followed by donor lymphocyte infusion (DLI) from HLA -haploidentical donors is a safe procedure that will not cause Graft ... (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation. Biological: DLI HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours ...

    Clinical Trial last updated 05/03/2016 - 9:59am.

  8. Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    ... 0.5-75 years Suitable first-degree related, HLA haploidentical or HLA-matched donor Eligible diagnoses: a. Low-grade non-Hodgkin's ...

    Clinical Trial last updated 05/02/2016 - 2:38pm.

  9. Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

    ... stem cell transplantation from a related or unrelated HLA matched donor. The effect of 5-azacytidine on global gene ...

    Clinical Trial last updated 05/02/2016 - 11:10am.

  10. Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

    ... be an 8/8 match for human leukocyte antigen ( HLA )-A, -B, and -C at intermediate (or higher) resolution, and -DRB1 at ... for donation1. Unrelated donor must be an 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated ...

    Clinical Trial last updated 06/06/2016 - 1:36pm.